Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (21)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  3. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

  4. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  5. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  6. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  3. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

    American Journal of Hematology

  4. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

  5. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  2. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

    Blood, Vol. 138, Núm. 19, pp. 1901-1905

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

2019

  1. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

  2. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8